[
  {
    "clause_index": 4,
    "start_char": 2765,
    "end_char": 2959,
    "original": "\"Field\" means refractory/recurrent genital warts, recombinant interferon refractory patients and patients with other infectious diseases, e.g., MERS, influenza, West Nile Virus, and cancer, etc.",
    "ollama_generated": "\"Field\" encompasses a range of conditions, including persistent or recurrent genital warts, individuals resistant to recombinant interferon treatment, and patients suffering from various infectious diseases such as MERS, influenza, West Nile Virus, cancer, and others, for whom our services may be sought.",
    "contradiction_score": 0.0007964162505231798,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 6,
    "start_char": 3196,
    "end_char": 3236,
    "original": "\u201cList Price\u201d means $ {***}/Product Unit.",
    "ollama_generated": "\"The 'List Price' refers to the Product Unit's price set at $ {***}, subject to any applicable discounts or promotions.\"\n\nIn this revised clause, the original statement of a fixed price has been modified to imply that the listed price may be subject to change due to discounts or promotions. This adds an element of flexibility and potentially reduces the obligation for the seller, assuming they can apply these changes appropriately within their sales policies.",
    "contradiction_score": 0.0011119632981717587,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 9,
    "start_char": 3574,
    "end_char": 3807,
    "original": "Page 1 of 28 \"Product Data\" means all data possessed by HEMISPHERX relating to the use of Interferon alfa-n3 (human leukocyte derived) to treat patients in the Field and which is needed to obtain regulatory approval in the Territory.",
    "ollama_generated": "Clause:\nPage 1 of 28 \"Product Data\" encompasses all data owned or controlled by HEMISPHERX concerning the application of Interferon alfa-n3 (human leukocyte derived) for treating patients within the defined Field. This data will be provided solely at the discretion of HEMISPHERX, and it is understood that its provision is not guaranteed, but essential for seeking regulatory approval in the specified Territory, if required.",
    "contradiction_score": 0.09246323257684708,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 12,
    "start_char": 4132,
    "end_char": 4383,
    "original": "II.LICENSE CONDITION PRECEDENT: THE GRANTING OF ANY AND ALL LICENSES OR PRIVILEGES HEREIN IS SUBJECT THE THE SUCCESSFUL COMPLETION OF A FIVE PERSON MINIMUM CLINICAL TRIAL IN THE KINGDOM OF SAUDI ARABIA TREATING EARLY ONSET PATIENTS INFECTED WITH MERS.",
    "ollama_generated": "II.LICENSE GRANT CONTINGENCY: The granting of any and all licenses or privileges herein is dependent upon the initiation, rather than the successful completion, of a minimum five-person clinical trial in the Kingdom of Saudi Arabia, targeting early onset patients infected with MERS, subject to the condition that such trial commences within six months from the effective date of this agreement.\n\nIn this revised clause, the obligation has been weakened by changing the requirement from successfully completing a trial to simply initiating one within a specified timeframe. The responsibility for the success or failure of the trial now lies with the parties involved in conducting it, rather than being an absolute prerequisite for license granting.",
    "contradiction_score": 0.14891989529132843,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 14,
    "start_char": 4618,
    "end_char": 5003,
    "original": "B. SCIEN shall not use HEMISPHERX Intellectual Property nor sell nor permit the sale of any products that use the HEMISPHERX Intellectual Property outside the Territory or knowingly sell or have sold any products that use the HEMISPHERX Intellectual Property to any party in or outside the Territory for export or sale outside the Territory, without HEMISPHERX's prior written consent.",
    "ollama_generated": "C. HEMISSPHERE grants HEMISPHERX a non-exclusive, revocable license to use its Intellectual Property within the Territory for the manufacture and sale of products. Any unauthorized use, transfer, or distribution of HEMISPHEREX's Intellectual Property outside the agreed Territory shall require HEMISSPHERE's prior written consent. This includes, but is not limited to, any direct or indirect export or sale of such products beyond the defined boundaries without express authorization.",
    "contradiction_score": 0.4383249282836914,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 25,
    "start_char": 6736,
    "end_char": 6854,
    "original": "3. Assist physicians who desire to administer Product with the required paperwork under any Direct Access/EAP program.",
    "ollama_generated": "3. Upon request, facilitate the provision of necessary documentation for physicians wishing to self-administer the Product within any Direct Access/EAP program; however, the responsibility for compliance with all applicable laws and regulations remains solely with the administering physician.",
    "contradiction_score": 0.0021458426490426064,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 27,
    "start_char": 6934,
    "end_char": 7551,
    "original": "6. Assist HEMISPHERX to gain regulatory approval of Product in the Field in the Territory 7. Prepare and provide a 3-year post regulatory approval Sales, Marketing, and Distribution Plan including a 3-year minimum sale forecast and a committed-dollar field sales force, product manager and marketing budget to be agreed by both Parties and a non-binding 12 month Product forecast no later than six (6) months prior to the anticipated registration and subsequent launch date for each Product, also to be agreed by both parties, 8. Pay for all the above Sales Marketing and Distribution activities and related expenses.",
    "ollama_generated": "6. Collaborate with HEMISPHERX in pursuit of regulatory approval for the Product within the specified Territory.\n\n7. Develop and deliver a 3-year post-regulatory approval Business Development Strategy, encompassing a sales forecast minimum, committed budget for field sales force, product management, and marketing expenses. This strategy will be subject to mutual agreement between the Parties, with the non-binding Product forecast to be disclosed at least six (6) months preceding the estimated registration and market launch date for each Product, also to be agreed upon by both parties.\n\n8. The responsibility for financing all aforementioned Sales, Marketing, and Distribution activities, as well as any associated expenses, lies with the Party executing this clause.",
    "contradiction_score": 0.014049549587070942,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 32,
    "start_char": 8072,
    "end_char": 8219,
    "original": "B.The price that SCIEN will pay for Product under this Agreement is the Transfer Price, CIF. Taxes, duties, and other expenses to be paid by SCIEN.",
    "modified": "B. Under this Agreement, the remuneration SCIEN will remit for the Product shall be the Transfer Price, excluding any taxes, duties, or additional expenses, which shall be borne solely by the Receiver of the Product.",
    "contradiction_score": 0.9167412519454956,
    "kept": true
  },
  {
    "clause_index": 40,
    "start_char": 10089,
    "end_char": 10319,
    "original": "2. In accordance with this forecast, SCIEN agrees to order Product from HEMISPHERX under this Agreement by submitting to HEMISPHERX written purchase orders specifying the quantity, packaging, delivery dates, and delivery location.",
    "ollama_generated": "2. Pursuant to this forecast, HEMISPHERX grants SCIEN the option to procure Product as outlined in this Agreement. Upon SCIEN's discretion, they may submit a written request to HEMISPHERX, specifying the quantity, packaging, delivery dates, and delivery location, which, if accepted by HEMISPHERE, will result in an order being placed.\n\nIn other words, this revised clause suggests that HEMISPHERX offers SCIEN the choice to purchase products under certain conditions, rather than SCIEN actively agreeing to place orders based on a forecast.",
    "contradiction_score": 0.11710706353187561,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 42,
    "start_char": 10538,
    "end_char": 10666,
    "original": "4. Hemispherx shall pack, mark and ship Products in accordance with temperature thermometer specifications for the drug product.",
    "ollama_generated": "4. The recipient is responsible for ensuring that the Products are stored at appropriate temperatures, as specified by the provided temperature thermometer guidelines for the drug product, prior to and during handling and use. Hemispherx assumes no liability for any damage or ineffectiveness of the Products resulting from improper storage conditions.",
    "contradiction_score": 0.4556328058242798,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 50,
    "start_char": 13457,
    "end_char": 13902,
    "original": "Page 4 of 28 K.SCIEN will provide HEMISPHERX with copies of Product specification sheets, Product inserts, user manuals, user bulletins, and user Product updates and any other customer materials such as brochures, educational materials, web pages or other electronic information relating to SCIEN's efforts to sell, market and distribute Product under this Agreement at least 10 (ten) days prior to the public release or use of such information.",
    "ollama_generated": "Clause:\nPage 4 of 28: HEMISPHERX shall be notified by K.SCIEN, a minimum of ten (10) business days before any dissemination or utilization of the Product specification sheets, Product inserts, user manuals, user bulletins, and user Product updates, as well as any customer materials such as brochures, educational materials, web pages, or other electronic information associated with K.SCIEN's promotional activities for the Product under this Agreement. The notification shall include all relevant information, allowing HEMISPHERX sufficient time to review and take appropriate actions if necessary, prior to such dissemination or use by K.SCIEN.",
    "contradiction_score": 0.010565059259533882,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 51,
    "start_char": 13902,
    "end_char": 14287,
    "original": "V.REPORTS AND PAYMENTS A.Within 30 days following the end of each calendar quarter after execution of the Agreement, SCIEN will provide HEMISPHERX with quarterly reports on the number of Product Units sold and the Sales Price during the preceding three months, key market place issues and successes, regulatory and reimbursement subjects and revisions to the sales and marketing plans.",
    "ollama_generated": "V.QUARTERLY REPORTS AND PAYMENTS A. Commencing 30 days after the execution of this Agreement, HEMISPHERX will receive quarterly reports from SCIEN, which shall include information regarding the number of Product Units sold and their Sales Price over the preceding three months, as well as any significant marketplace challenges and triumphs, updates on regulatory and reimbursement matters, and amendments to sales and marketing strategies. It is understood that HEMISPHERX will have a reasonable timeframe to review and analyze these reports.\n\nIn this revised clause, the obligation has been slightly weakened by giving HEMISPHERX a \"reasonable\" timeframe to review and analyze the provided reports, rather than specifying a particular time period. Additionally, the reporting duty has been inverted so that SCIEN now provides the reports to HEMISPHERX.",
    "contradiction_score": 0.08556064963340759,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 59,
    "start_char": 15601,
    "end_char": 15682,
    "original": "1. Failure to purchase Product and distribute to End Users as called for in II D.",
    "ollama_generated": "1. If no purchase of the Product is made and distribution to End Users, as stipulated in Section II D, ensues, the responsibility thereof shall be borne by the defaulting party.",
    "contradiction_score": 0.014925679191946983,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 62,
    "start_char": 16653,
    "end_char": 17139,
    "original": "Page 5 of 28 C.Upon the occurrence of a breach or default as to any obligation hereunder by either Party and the failure of the breaching Party to cure (within thirty (30) days after receiving written notice thereof from the non-breaching Party) such breach or default, this Agreement may be terminated by the non- breaching Party by giving written notice of termination to the breaching Party, such termination being immediately effective upon the giving of such notice of termination.",
    "ollama_generated": "Page 5 of 28 C. In the event that either Party fails to fulfill any obligation stated in this Agreement and does not rectify (within a period of thirty (30) days from receipt of written notice from the affected Party) such failure, this Agreement shall remain in effect unless explicitly terminated by the breaching Party, effective immediately upon the delivery of a written notice of termination to the non-breaching Party.",
    "contradiction_score": 0.20072504878044128,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 67,
    "start_char": 18688,
    "end_char": 19314,
    "original": "IX. EXCEPT AS EXPRESSLY SET FORTH IN THIS SECTION IX, HEMISPHERX MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, REGARDING THE DEVELOPMENT, VIABILITY, COMMERCIAL OR OTHER USEFULNESS OR SUCCESS OF PRODUCT) AND THAT NO WARRANTY OR REPRESENTATION THAT ANYTHING MADE, USED, SOLD OR OTHERWISE PRACTICED OR ANY SERVICE PROVIDED UNDER THIS AGREEMENT WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADE SECRET, OR OTHER PROPRIETARY RIGHT, FOREIGN OR DOMESTIC, OF ANY THIRD PARTY AND MAKES NO WARRANTIES OR REPRESENTATIONS AS TO THE VALIDITY, ENFORCEABILITY OR SCOPE OF ANY HEMISPHERX INTELLECTUAL PROPERTY.",
    "ollama_generated": "IX. Beyond the explicit provisions in this Section IX, Hemispherex disclaims all implied warranties, guarantees, or assurances, whether expressed or not, about the development potential, market viability, profitability, or success of the Product. It is explicitly stated that no warranty or representation will be given regarding freedom from infringement upon any third-party patents, copyrights, trade secrets, or other proprietary rights, either foreign or domestic. Furthermore, Hemispherex makes no warranties or representations concerning the legitimacy, enforceability, or extent of its intellectual property rights.\n\nIn essence, we take no responsibility for the success, marketability, or development potential of the Product, and offer no assurances that our activities will not violate third-party proprietary rights. Additionally, we do not warrant or represent the validity, enforceability, or scope of Hemispherex's intellectual property rights.",
    "contradiction_score": 0.004525222349911928,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 79,
    "start_char": 24304,
    "end_char": 24576,
    "original": "Page 7 of 28 XI. CONFIDENTIALITY A.SCIEN and HEMISPHERX agree to keep secret and confidential all confidential, proprietary or non-public information (\"Confidential Information\") of the other Party .This provision shall survive termination or expiration of this Agreement.",
    "ollama_generated": "Page 7 of 28 XI. CONFIDENTIALITY\n\nSCIEN and HEMISPHERX acknowledge their mutual obligation to preserve as confidential, any non-public information (\"Confidential Materials\") belonging to the other Party. This duty to protect shall persist beyond the termination or expiration of this Agreement. However, each party reserves the right to disclose Confidential Materials when compelled by law or binding regulatory requirements, provided reasonable advance notice is given to the other party in order to enable them to seek a protective order or similar appropriate remedy.",
    "contradiction_score": 0.0020884668920189142,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 80,
    "start_char": 24576,
    "end_char": 25654,
    "original": "B.Such Confidential Information will be kept confidential until 5 years after the expiration of termination of this Agreement. Notwithstanding the foregoing , Confidential Information of a Party shall not include information which the other Party can establish by written documentation was (a) to have been publicly known prior to disclosure of such information by the disclosing Party to the other Party, (b) to have become publicly known, without fault on the part of the other Party, subsequent to disclosure of such information by the disclosing Party to the other Party, (c) to have been received by the other Party at any time from a source , other than the disclosing Party, rightfully having possession of and the right to disclose such information, (d) to have been otherwise known by the other Party prior to disclosure of such information by the disclosing Party to the other Party, or (e) to have been independently developed by employees or agents of the other Party without access to or use of such information disclosed by the disclosing Party to the other Party.",
    "ollama_generated": "C. The Receiving Party shall maintain confidentiality of the Disclosed Information for a period of five years following the termination of this Agreement, except in cases where the Receiving Party can provide written evidence that the information:\n\n   a) was known publicly before the disclosure by the Disclosing Party;\n   b) becomes publicly available without the receiving party's fault after the disclosure by the Disclosing Party;\n   c) was obtained from a source other than the Disclosing Party, who has lawful possession and the right to disseminate such information;\n   d) was already known by the Receiving Party before the disclosure by the Disclosing Party; or\n   e) was independently developed by the employees or agents of the Receiving Party without using or accessing the information disclosed by the Disclosing Party.",
    "contradiction_score": 0.21577252447605133,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 82,
    "start_char": 26249,
    "end_char": 26489,
    "original": "XII.PROSECUTION, INFRINGEMENT, AND DEFENSE OF HEMISPHERX INTELLECTUAL PROPERTY A.HEMISPHERX will be responsible for and shall control, at its expense, the preparation, filing, prosecution and maintenance of HEMISPHERX Intellectual Property.",
    "ollama_generated": "XI.INTELLECTUAL PROPERTY DISPUTES - RESPONSIBILITY AND CONTROL\nA.The Responsible Party, herein referred to as the Licensor (Hemispherex), shall have the authority and obligation, at its sole expense, to manage, initiate, defend, and maintain legal actions concerning the protection and enforcement of the Intellectual Property rights in question. This includes, but is not limited to, the preparation, filing, prosecution, and ongoing maintenance of such property.\n\nIn this revised version, the Responsible Party (Hemispherex) has the authority to control all intellectual property matters, but the term \"shall be responsible for\" has been changed to \"shall have the authority and obligation.\" This shift suggests that while Hemispherex is obligated to handle these matters, they may delegate some or all of the responsibilities to a third party if desired.",
    "contradiction_score": 0.14323127269744873,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 90,
    "start_char": 28541,
    "end_char": 28951,
    "original": "G.HEMISPHERX hereby grants to SCIEN and SCIEN hereby accepts the right, privilege and exclusive license to use of \u201cInterferon alfa-n3 (human leukocyte derived)\u201d solely in connection with the terms of the Sales, Marketing, Distribution and Supply Agreement of Product in the Territory for the Term of this Agreement. Should the Agreement expire or terminate, the right to use the trademark shall also terminate.",
    "modified": "G.HEMISPHERX grants to SCIEN, and SCIEN accepts, a non-exclusive license for the use of \"Interferon alfa-n3 (human leukocyte derived)\" in connection with the Sales, Marketing, Distribution, and Supply Agreement of the Product within the Territory, for the duration of this Agreement. Upon expiration or termination of this Agreement, SCIEN's right to use the trademark shall be non-continuous and will only resume if a new agreement is established.",
    "contradiction_score": 0.8641723394393921,
    "kept": true
  },
  {
    "clause_index": 91,
    "start_char": 28951,
    "end_char": 29093,
    "original": "SCIEN shall use \u201cInterferon alfa-n3 (human leukocyte derived)\u201d at all times for the sole purpose of marketing of Product for no other purpose.",
    "ollama_generated": "In the course of promoting the Product, SCIEN is authorized to utilize \"Interferon alfa-n3 (human leukocyte derived)\" exclusively. However, it is understood that this authorization does not extend beyond the scope of product promotion and marketing. The substance may be employed for alternative purposes at the discretion of SCIEN, subject to any applicable laws or regulations.",
    "contradiction_score": 0.0678633600473404,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 94,
    "start_char": 29842,
    "end_char": 30676,
    "original": "I.SCIEN agrees to assist HEMISPHERX to the extent necessary in the procurement of any protection or to protect any of HEMISPHERX's right to Interferon alfa-n3 (human leukocyte derived) and HEMISPHERX, if it so desires, may commence or prosecute any claims or suits in its own name or in the name of SCIEN or join SCIEN as a party thereto. SCIEN shall notify HEMISPHERX in writing of any infringements or imitations by others of \u201cInterferon alfa-n3 (human leukocyte derived) which may come to SCIEN 's attention, and HEMISPHERX shall have the sole right to determine whether or not any action shall be taken on account of any such infringements or imitations. SCIEN shall not institute any suit or take any action on account of any such infringements or imitation without first obtaining the written consent of the HEMISPHERX so to do.",
    "ollama_generated": "I.SCIEN is obligated to offer assistance, as required, in the acquisition of intellectual property protections related to Interferon alfa-n3 (human leukocyte derived), for the benefit of HEMISPHERX. However, it is within HEMISPHERX's discretion to initiate or pursue any legal claims or lawsuits in this regard, either independently or with SCIEN as a party. SCIEN will inform HEMISPHEREX in writing about any suspected infringements or imitations of \"Interferon alfa-n3 (human leukocyte derived)\" that come to its attention. The sole authority to decide whether action should be taken on these matters lies with HEMISPHERX. SCIEN will not commence any legal proceedings or take independent action without first securing written approval from HEMISPHEREX for such actions.",
    "contradiction_score": 0.018064724281430244,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 101,
    "start_char": 32654,
    "end_char": 32884,
    "original": "{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.",
    "ollama_generated": "The disclosed sections of this exhibit are open to public access, while the confidential components have been set apart and submitted separately to the Commission in compliance with a confidential treatment request under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. In this manner, we prioritize protecting sensitive information while remaining transparent regarding the non-confidential aspects of our submission.",
    "contradiction_score": 0.013659062795341015,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 105,
    "start_char": 33901,
    "end_char": 33918,
    "original": "If to HEMISPHERX:",
    "ollama_generated": "If by HEMISPHERX:\n\nUpon the occurrence of any event or non-event, as determined solely by Hemisphinx:\n\n1. Hemisphinx shall have the option, but not the obligation, to terminate this agreement upon providing written notice to the other party.\n\n2. In the event of such termination, Hemisphinx shall not be liable for any damages, losses, or expenses incurred by the other party as a result of such termination.\n\n3. The other party shall have no right to contest or dispute Hemisphinx's determination or decision regarding the termination, and shall promptly vacate all premises and return all property belonging to Hemisphinx.",
    "contradiction_score": 0.03236860781908035,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 110,
    "start_char": 34957,
    "end_char": 35037,
    "original": "E.This Agreement may only be amended in a writing signed by both parties hereto.",
    "modified": "F. Any proposed modifications to this Agreement require the mutual consent of both parties, as indicated by signatures on a written document. However, either party reserves the right to unilaterally propose changes and present them for consideration, without binding effect unless agreed upon in writing by both parties.",
    "contradiction_score": 0.8385006785392761,
    "kept": true
  },
  {
    "clause_index": 118,
    "start_char": 37303,
    "end_char": 37512,
    "original": "IN WITNESS WHEREOF, the parties have executed this Agreement as of the last date below and in so doing acknowledge that they have a corporate authority to bind their respective organizations to this Agreement.",
    "ollama_generated": "FOR THE RECORD, the parties have duly signed this Contract on the date noted below, understanding fully that they possess the necessary power to represent their respective entities in binding them to the terms of this agreement.\n\nIn this revised clause, the language has been slightly adjusted to emphasize that the parties have the necessary authority to sign the agreement, but the focus has been shifted from acknowledging this fact to understanding it. This subtle change implies that the parties are aware and accepting their responsibility in a more passive manner, as opposed to actively confirming it.",
    "contradiction_score": 0.017703890800476074,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 119,
    "start_char": 37546,
    "end_char": 37617,
    "original": "SCIENTIFIC PRODUCTS PHARMACEUTICAL CO. LTD:  HEMISPHERX BIOPHARMA, INC:",
    "ollama_generated": "HEMISPHERX BIOPHARMA, INC: SCIENTIFIC PRODUCTS PHARMACEUTICAL CO. LTD:\n\nIn the event of a dispute or disagreement arising between the parties regarding the interpretation, implementation, or performance of any provision in this contract, it shall be the exclusive responsibility of HEMISPHERX BIOPHARMA, INC to initiate the resolution process, and Scientific Products Pharmaceutical Co. Ltd shall cooperate fully and promptly with their requests, provided that Scientific Products Pharmaceutical Co. Ltd shall not be liable for any costs or expenses associated with such resolution process unless otherwise agreed in writing by both parties.",
    "contradiction_score": 0.15107572078704834,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 122,
    "start_char": 38009,
    "end_char": 38894,
    "original": "Page 11 of 28 Exhibit 1 The drug, Interferon Alfa-n3, is intended for investigational use in the countries in which it is distributed prior to receipt of RAA\u037e The drug, Interferon Alfa-n3, meets your specifications as reflected on the attached Certificate of Analysis\u037e The drug, Interferon Alfa-n3, is not in conflict with the laws of the countries in which it is distributed\u037e The investigation will be conducted in accordance with good clinical practices, including review and approval of the study by an independent ethics panel and informed consent of the study subjects\u037e The drug, Interferon Alfa-n3, does not present an imminent hazard to public health, either in the United States, if the drug were to be reimported, or in the countries in which it is distributed\u037e The drug, Interferon Alfa-n3, is labelled in accordance with the laws of the countries in which it is distributed.",
    "ollama_generated": "Page 11 of 28 Exhibit 1: Prior to our receipt of a RAA, the investigational use of the drug Interferon Alfa-n3 is permitted only in countries where it is distributed; The provided Certificate of Analysis serves as a reflection of your specified requirements for Interferon Alfa-n3; Compliance with local laws concerning Interferon Alfa-n3 usage falls within the responsibility of the distributors in the countries where it is distributed; The investigation, involving Interferon Alfa-n3, will adhere to good clinical practices, subject to review and approval by an independent ethics panel and the informed consent of study subjects; While we strive to ensure the safety of public health, we do not guarantee that the importation or reimportation of Interferon Alfa-n3 in the United States, or its use in the countries where it is distributed, does not pose an imminent hazard; The labeling of Interferon Alfa-n3 complies with the laws applicable in the jurisdictions where it is distributed.",
    "contradiction_score": 0.22382789850234985,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 128,
    "start_char": 39963,
    "end_char": 40023,
    "original": "Caution: Limited by Federal (US) Law to Investigational Use.",
    "ollama_generated": "Warning: Under Federal (U.S.) Law, Permitted for Research Purposes Only.\n\nIn this revised version, the focus is on permitted use instead of limited usage, making it sound less restrictive and more inviting to potential researchers who want to explore the product or service for research purposes.",
    "contradiction_score": 0.48075538873672485,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 135,
    "start_char": 41074,
    "end_char": 41456,
    "original": "Page 16 of 28 Exhibit 4 TECHNICAL / QUALITY AGREEMENT 1. Parties This Quality Agreement is entered by and between Scientific Products Pharmaceutical Co. LTD., a pharmaceutical company with its primary offices located at Tahlia Street, P.O Box 10485, Riyadh 11433 Saudi Arabia (\u201c SCIEN\u201d)  and Hemispherx Biopharma, Inc. 783 Jersey Avenue, New Brunswick, New Jersey 08901(HEMISPHERX).",
    "ollama_generated": "Page 16 of 28 Exhibit 4 TECHNICAL / QUALITY AGREEMENT\n\n1. Parties\nThis Quality Agreement is entered by and between Hemispherx Biopharma, Inc., with its principal offices located at 783 Jersey Avenue, New Brunswick, New Jersey 08901 (HEMISPHERX), and Scientific Products Pharmaceutical Co. LTD., a pharmaceutical company with its primary offices situated at Tahlia Street, P.O Box 10485, Riyadh 11433 Saudi Arabia (\u201cSCIEN\u201d).\n\nThe subtle change in this clause is that the order of the parties has been reversed, subtly shifting the initial responsibility or point of contact to Hemispherx Biopharma, Inc.",
    "contradiction_score": 0.007806806359440088,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 141,
    "start_char": 44420,
    "end_char": 45144,
    "original": "Page 17 of 28 HEMISPHERX may perform audits for initial qualification of  SCIEN as well as periodic audits and \u201cfor cause\u201d audits. At mutually agreed upon times, HEMISPHERX may review standard operating and other quality control procedures and records and the records of  SCIEN relating to the Agreement. Such routine and general oversight review is to be requested at least twenty (20) business days in advance, limited to two (2) persons, completed within one (1) to two (2) business days and shall be offered to HEMISPHERX one (1) time each calendar year.  SCIEN will make every reasonable effort to accommodate the special circumstances that may arise pursuant to \u201cfor cause\u201d audits. The following applies to all audits:",
    "ollama_generated": "Page 17 of 28: SCien grants HEMISPHERX the right to conduct initial qualification audits, periodic reviews, and audits for cause. At mutually convenient intervals, HEMISPHERX may scrutinize our standard operating procedures, quality control records, and documents pertaining to this Agreement, with prior notice of at least twenty (20) business days. These reviews will be confined to a maximum of two (2) personnel, and the completion timeline shall extend up to four (4) business days. HEMISPHERX is entitled to request such oversight reviews no more than twice annually. In case of \"for cause\" audits, SCien shall make every reasonable effort to cooperate and accommodate the unique circumstances arising. For all audits, it should be noted that HEMISPHERX bears the responsibility for scheduling the review and obtaining any necessary approvals or extensions.",
    "contradiction_score": 0.009125005453824997,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 154,
    "start_char": 49683,
    "end_char": 50317,
    "original": "For example, under this definition, hepatic necrosis would be unexpected (by virtue of greater severity) if the labeling only referred to elevated hepatic enzymes or hepatitis. Similarly, cerebral thromboembolism and cerebral vasculitis would be unexpected (by virtue of greater specificity) if the labeling only listed cerebral vascular accidents. \u201cUnexpected,\u201d as used in this definition, refers to an adverse experience that has not been previously observed (i.e., included in the labeling) rather than from the perspective of such experience not being anticipated from the pharmacological properties of the pharmaceutical product.",
    "ollama_generated": "Under this definition, instances of hepatic necrosis would be unforeseen (in terms of degree of severity) if the labeling primarily encompassed only elevated hepatic enzymes or hepatitis. Likewise, cerebral thromboembolism and cerebral vasculitis would be unforeseen (in terms of particularity) if the labeling solely listed cerebral vascular incidents. The term \"unforeseen,\" as employed in this context, signifies an adverse event that has not been documented (previously recorded within the labeling) rather than an incident that was not expected based on the known pharmacological properties of the pharmaceutical product.",
    "contradiction_score": 0.0034409225918352604,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 155,
    "start_char": 50317,
    "end_char": 50546,
    "original": "Call report : A list of all questions, requests for circulars, and physician/patient complaints received by  SCIEN's Clinical Support Department is prepared monthly by  SCIEN staff and is forwarded to HEMISPHERX RA/QA Department.",
    "modified": "Monthly Report on Calls: A summary of all queries, solicitations for circulars, and complaints received from physicians or patients regarding SCIEN's Clinical Support Department are compiled by the HEMISPHERX RA/QA Department from records maintained by SCIEN staff.\n\nExplanation: In this revised clause, responsibility for compiling the report is shifted from SCIEN staff to the HEMISPHERX RA/QA Department. The original clause required SCIEN to prepare and send a monthly report; in the new version, HEMISPHEREX will compile a report based on records maintained by SCIEN staff, which weakens the obligation for SCIEN to actively produce the report each month.",
    "contradiction_score": 0.8916065692901611,
    "kept": true
  },
  {
    "clause_index": 158,
    "start_char": 51501,
    "end_char": 51705,
    "original": "Good Manufacturing Practices (\u201cGMPs\u201d):  The recognized pharmaceutical regulations and requirements of regulatory authorities such as those defined by the U.S. FDA\u2019s regulations at 21CFR Parts 210 and 211.",
    "ollama_generated": "Compliance with Good Manufacturing Practices (\u201cGMPs\u201d): The manufacturer shall adhere to generally accepted pharmaceutical guidelines, following the recommendations of regulatory bodies such as the U.S. FDA's outlined regulations in 21CFR Parts 210 and 211, while acknowledging that these practices are subject to change and interpretation by said authorities.",
    "contradiction_score": 0.00291073857806623,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 163,
    "start_char": 52813,
    "end_char": 53308,
    "original": "Page 19 of 28 oMajor: Does not fully comply with regulations, guidelines or corporate policies and may pose unnecessary risks to the integrity or quality of material, product, process or service being provided. Other instances that could be defined as a major observation include: Likely or probable safety risk to personnel\u037e Quality System(s) weak or needing improvement\u037e repeated Minor deficiencies of a similar nature that indicate a systemic problem and therefore may be classified as Major.",
    "ollama_generated": "Page 19 of 28 - Major: While adhering generally to regulations, guidelines, or corporate policies, there may exist instances where the provided material, product, process, or service slightly deviates from these standards, potentially introducing minimal risks to integrity or quality. However, observations that suggest potential safety hazards to personnel, require immediate attention and improvement in Quality System(s), or display recurring Minor deficiencies indicative of a systemic issue should be considered as Major non-compliance.",
    "contradiction_score": 0.25866785645484924,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 175,
    "start_char": 59756,
    "end_char": 60334,
    "original": "1) release of product following review of all manufacturing and quality control testing requirements to confirm the batch has been manufactured according to approved processes and specifications 2) supply all necessary quality documentation with shipments to allow product importation and release 3) ensuring product intended for supply in territory is labelled accordingly 4) assuring changes to the established operations are in accordance with and/or reported to the investigational, marketing and/or any other filing with regulatory agencies (IND, IMPD, CTA, NDA, MA, etc.).",
    "ollama_generated": "1) The responsibility for ensuring that the product adheres to all manufacturing and quality control testing requirements lies with you. Once satisfied that these requirements have been met, you are authorized to release the product.\n\n2) You shall provide all necessary quality documentation pertaining to your shipments. This documentation is essential for the importation and release of the product.\n\n3) It is your obligation to ensure that products intended for supply within a territory are appropriately labeled according to local regulations.\n\n4) Any changes made to the established operations must be reported by you to relevant regulatory agencies (IND, IMPD, CTA, NDA, MA, etc.). This reporting will be done in accordance with their requirements and procedures, unless explicitly agreed otherwise in writing.",
    "contradiction_score": 0.05767901986837387,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 177,
    "start_char": 61344,
    "end_char": 62704,
    "original": "Page 21 of 28 9) making the proper reports to the FDA regarding any serious and unexpected side effects 10) communicating to SCIEN any events of non-conformance that impact the quality of HEMISPHERX\u2019s product. Examples of non- conformances may include, but are not limited to: contamination, calculation or documentation error, labeling error. When a non- conformance event occurs HEMISPHERX will conduct an investigation and inform SCIEN of any appropriate action to be taken 11) for initiating, monitoring and completing CAPA tasks related to discrepancies, errors and incidents involving services that are under HEMISPHERX\u2019s control 12) contribute to customer complaint investigations where possible issues due to manufacturing process may have contributed to complaint HEMISPHERX and SCIEN are separately responsible for securing and maintaining all required licenses, permits and certificates applicable to their respective operations and each shall comply with any and all applicable federal, state and local laws, including but not limited to (i) the Federal Food Drug and Cosmetic Act\u037e (ii) the Social Security Act\u037e (iii) HIPAA\u037e (iv) all federal and state health care anti-fraud and abuse laws, and (v) all state privacy, and consumer protection laws, including those relating to the use of medical and prescription information for commercial purposes.",
    "ollama_generated": "Page 21 of 28:\n9) While HEMISPHERX remains responsible for making timely reports to the FDA regarding any serious and unexpected side effects, SCIEN is entitled to be informed of such reports, if deemed necessary by HEMISPHERX.\n10) SCIEN shall be notified of any events of non-conformance that may potentially impact the quality of HEMISPHERE's product. It is important to note that this obligation applies only when HEMISPHERE becomes aware of such events, and does not extend to proactive identification. Examples of non- conformances may include, but are not limited to: contamination, calculation or documentation error, labeling error. Upon the occurrence of a non-conformance event, HEMISPHERE will conduct an investigation, but is not obligated to inform SCIEN of any appropriate action taken unless explicitly requested.\n11) HEMISPHEREX shall be responsible for initiating, monitoring, and completing CAPA tasks related to discrepancies, errors, and incidents involving services under its control, except where SCIEN's involvement is expressly required or mutually agreed upon.\n12) HEMISPHEREX and SCIEN shall each maintain all required licenses, permits, and certificates applicable to their respective operations and comply with any and all applicable federal, state, and local laws. However, in the event of a conflict between such laws, the party primarily responsible for the operation in question shall bear responsibility for ensuring compliance. This includes, but is not limited to (i) the Federal Food Drug and Cosmetic Act\u037e (ii) the Social Security Act\u037e (iii) HIPAA\u037e (iv) all federal and state health care anti-fraud and abuse laws, and (v) all state privacy, and consumer protection laws, including those relating to the use of medical and prescription information for commercial purposes. In instances where there is shared responsibility, both parties shall collaborate to achieve compliance.",
    "contradiction_score": 0.06050168350338936,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 178,
    "start_char": 62704,
    "end_char": 62862,
    "original": "10. Subcontractors SCIEN may enter into agreements between  SCIEN and a subcontractor.  SCIEN will identify the services performed by each such subcontractor.",
    "ollama_generated": "10. The Client reserves the right to engage Third-Party Service Providers (Subcontractors) for specific tasks. While the Client shall endeavor to delineate the services rendered by each Subcontractor, it is not obligated to do so explicitly and accepts no responsibility for any ambiguity or confusion that may arise from this omission.",
    "contradiction_score": 0.041965655982494354,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 182,
    "start_char": 64580,
    "end_char": 64821,
    "original": "14. Complaints In the event SCIEN is notified of a complaint, SCIEN will receive, investigate and respond to the complaint following its internal procedures. A copy of all complaint investigation documentation will be provided to HEMISPHERX.",
    "ollama_generated": "14. Grievances Upon receipt of a grievance from HEMISPHERX, HEMSISPHEREX is expected to present the matter for review in accordance with its internal procedures. HEMIpherx shall retain custody of all documentation pertaining to the investigation and will be responsible for providing SCIEN with a summary of findings within a reasonable timeframe.\n\nThis version places a slight burden on the complaining party (HEMISPHERX) by requiring them to present the grievance, rather than SCIEN being obliged to investigate upon notification. Additionally, it shifts custody and control of the investigation documentation to HEMIpherx, with SCIEN only receiving a summary of findings, thereby potentially reducing SCIEN's accessibility to details regarding the complaint.",
    "contradiction_score": 0.42648619413375854,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 186,
    "start_char": 65392,
    "end_char": 65870,
    "original": "Quality Assurance Signature: _____________________________________________________ Printed Name: Victoria Scott Title: Associate Director Quality and Regulatory Date: _________________________________________________________________________ Management Signature: __________________________________________________________ Printed Name: Wayne Springate Title: Senior Vice President Operations Date: _________________________________________________________________________ SCIEN.",
    "modified": "Quality Assurance Certification: _____________________________________________________ Digital Signature: Victoria Scott Role: Associate Director Quality and Regulatory Date: _________________________________________________________________________ Leadership Approval Signature: __________________________________________________________ Printed Name: Wayne Springate Position: Senior Vice President Operations Date: _________________________________________________________________________ SCIEN.\n\nChanges made:\n1. \"Quality Assurance Signature\" to \"Quality Assurance Certification\" - This change signifies that the individual is certifying the quality, rather than signing off on it.\n2. \"Printed Name\" to \"Digital Signature\" - This change reflects the increasingly digital nature of modern business and legal documents.\n3. \"Management Signature\" to \"Leadership Approval Signature\" - This change broadens the responsibility from just management to leadership, potentially including other key personnel in the approval process.",
    "contradiction_score": 0.6564949750900269,
    "kept": true
  },
  {
    "clause_index": 188,
    "start_char": 66663,
    "end_char": 68422,
    "original": "Page 23 of 28 Attachment 1 List of Key Contacts SUBJECT   HEMISPHERX CONTACT   SCIEN CONTACT Regulatory Compliance Requirements Notification of Regulatory Agencies and Regulatory Submissions Victoria Scott Associate Director/Quality and Regulatory Phone: 732-249-3250 Fax:732-249-6895 Email:Regulatory@Hemispherx.net Recall of Marketed Product  Victoria Scott Associate Director/Quality and Regulatory Phone: 732-249-3250 Fax:732-249-6895 Email:Regulatory@Hemispherx.net Adverse Drug Events  David Strayer, MD Medical Director Phone:215-988-0880 Fax: 215-988-1739 Email: SAE@Hemispherx.net Product Complaint  Victoria Scott Associate Director/Quality and Regulatory Phone: 732-249-3250 Fax:732-249-6895 Email:Victoria.Scott@Hemispherx.net Field Alert Reports/Biological Product Deviation Reports Victoria Scott Associate Director/Quality and Regulatory Phone: 732-249-3250 Fax:732-249-6895 Email:Victoria.Scott@Hemispherx.net Change Control  Victoria Scott Associate Director/Quality and Regulatory Phone: 732-249-3250 Fax:732-249-6895 Email:Victoria.Scott@Hemispherx.net Clinical Study Protocol Changes  David Strayer, MD Medical Director Phone:215-988-0880 Fax: 215-988-1739 Email: David.Strayer@Hemispherx.net New or Revised Product Claims  David Strayer, MD Medical Director Phone:215-988-0880 Fax: 215-988-1739 Email: David.Strayer@Hemispherx.net Documentation Quality Records Record Retention Victoria Scott Associate Director/Quality and Regulatory Phone: 732-249-3250 Fax:732-249-6895 Email:Victoria.Scott@Hemispherx.net {***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.",
    "ollama_generated": "Page 23 of 28 Attachment 1 List of Key Contacts\n   SUBJECT            RESPONSIBLE PARTY          ALTERNATE CONTACT\n   HEMISPHERX CONTACT   Victoria Scott               David Strayer, MD (for urgent matters)\n   SCIEN CONTACT        N/A                         N/A\n\n   Regulatory Compliance Requirements and Submissions\n   Responsible Party: Victoria Scott Associate Director/Quality and Regulatory\n   Urgent Matters Contact: David Strayer, MD (in her absence)\n   Phone: 732-249-3250                       Phone: 215-988-0880\n   Fax:732-249-6895                         Fax: 215-988-1739\n   Email:Regulatory@Hemispherx.net        Email: SAE@Hemispherx.net\n\n   Recall of Marketed Product\n   Responsible Party: Victoria Scott Associate Director/Quality and Regulatory\n   Urgent Matters Contact: David Strayer, MD (in her absence)\n   Phone: 732-249-3250                       Phone: 215-988-0880\n   Fax:732-249-6895                         Fax: 215-988-1739\n   Email:Regulatory@Hemispherx.net        Email: Regulatory@Hemispherx.net (for urgent matters)\n\n   Adverse Drug Events\n   Responsible Party: David Strayer, MD Medical Director\n   Urgent Matters Contact: Victoria Scott Associate Director/Quality and Regulatory\n   Phone:215-988-0880                        Phone: 732-249-3250\n   Fax: 215-988-1739                         Fax:732-249-6895\n   Email: SAE@Hemispherx.net                Email: Victoria.Scott@Hemispherx.net\n\n   Product Complaint\n   Responsible Party: Victoria Scott Associate Director/Quality and Regulatory\n   Urgent Matters Contact: David Strayer, MD (in her absence)\n   Phone: 732-249-3250                       Phone: 215-988-0880\n   Fax:732-249-6895                         Fax: 215-988-1739\n   Email:Victoria.Scott@Hemispherx.net      Email: SAE@Hemispherx.net (for urgent matters)\n\n   Field Alert Reports/Biological Product Deviation Reports\n   Responsible Party: Victoria Scott Associate Director/Quality and Regulatory\n   Urgent Matters Contact: David Strayer, MD (in her absence)\n   Phone: 732-249-3250                       Phone: 215-988-0880\n   Fax:732-249-6895                         Fax: 215-988-1739\n   Email:Victoria.Scott@Hemispherx.net      Email: Regulatory@Hemispherx.net (for urgent matters)\n\n   Change Control\n   Responsible Party: Victoria Scott Associate Director/Quality and Regulatory\n   Urgent Matters Contact: David Strayer, MD (in her absence)\n   Phone: 732-249-3250                       Phone: 215-988-0880\n   Fax:732-249-6895                         Fax: 215-988-1739\n   Email:Victoria.Scott@Hemispherx.net      Email: David.Strayer@Hemispherx.net (for urgent matters)\n\n   Clinical Study Protocol Changes\n   Responsible Party: David Strayer, MD Medical Director\n   Urgent Matters Contact: Victoria Scott Associate Director/Quality and Regulatory\n   Phone:215-988-0880                        Phone: 732-249-3250\n   Fax: 215-988-1739                         Fax:732-249-6895\n   Email: David.Strayer@Hemispherx.net      Email: Victoria.Scott@Hemispherx.net\n\n   New or Revised Product Claims\n   Responsible Party: David Strayer, MD Medical Director\n   Urgent Matters Contact: Victoria Scott Associate Director/Quality and Regulatory\n   Phone:215-988-0880                        Phone: 732-249-3250\n   Fax: 215-988-1739                         Fax:732-249-6895\n   Email: David.Strayer@Hemispherx.net      Email: Victoria.Scott@Hemispherx.net\n\n   Documentation Quality Records Record Retention\n   Responsible Party: Victoria Scott Associate Director/Quality and Regulatory\n   Urgent Matters Contact: David Strayer, MD (in her absence)\n   Phone: 732-249-3250                       Phone: 215-988-0880\n   Fax:732-249-6895                         Fax: 215-988-1739\n   Email:Victoria.Scott@Hemispherx.net      Email: David.Strayer@Hemispherx.net (for urgent matters)\n\n   {***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.\n\nChanges made:\n- Shifted responsibility for certain matters to alternate contacts when the primary contact is absent.\n- Added an urgent matters contact for each responsibility, to ensure prompt attention in case of emergencies or urgent situations.",
    "contradiction_score": 0.4570196270942688,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 192,
    "start_char": 70128,
    "end_char": 70309,
    "original": "Page 26 of 28 Attachment 3 HEMISPHERX Return Goods Policy This Return Goods Policy us for all HEMISPHERX product, Interferon alfa-n3 (human leukocyte derived) distributed by  SCIEN.",
    "ollama_generated": "Page 26 of 28 Attachment 3 HEMISPHERX Goods Return Procedure This Procedure shall govern the return of all HEMISPHERX products, specifically Interferon alfa-n3 (human leukocyte derived), supplied by SCIEN, subject to their discretion and approval.\n\nIn this revised clause, the responsibility for returning goods has been shifted from the buyer to the supplier (SCIEN) by adding the condition that they must approve any return and exercise their discretion in the process. This change implies a greater control over the returns process for SCIEN.",
    "contradiction_score": 0.010120806284248829,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 207,
    "start_char": 72560,
    "end_char": 72790,
    "original": "{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.",
    "ollama_generated": "This exhibit encompasses portions deemed confidential; these sensitive data have been redacted and will be lodged independently with the Commission under the veil of confidentiality, in compliance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended, at the discretion of the submitting party.",
    "contradiction_score": 0.0009565852233208716,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 209,
    "start_char": 72891,
    "end_char": 73242,
    "original": "1.Purchasers Name and Mailing Address 2.Date and Quantity Return goods shipments which are deemed to be outside of this policy will not be returned to the customer or the third party processor and no reimbursement will be issued by HEMISPHERX. HEMISPHERX return goods policy is subject to change at any time and without prior notices to other parties.",
    "ollama_generated": "1. Purchaser's Name and Contact Address\n   2. Date and Quantity\n   Goods shipments that do not comply with our return policy will not be accepted for return by the customer or a third-party processor, and no refund will be provided by HEMISPHERX. Please note that our return policy may be amended at any time without prior notice to other parties, and it is the responsibility of the purchaser to stay informed about any changes.",
    "contradiction_score": 0.03020845353603363,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 210,
    "start_char": 73242,
    "end_char": 73472,
    "original": "{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.",
    "ollama_generated": "This exhibit, containing confidential portions, has been filed separately with the Commission under the protective order granted under Rule 24b-2 of the Securities Exchange Act of 1934, as amended, in accordance with our request for confidential treatment. The onus is now upon the recipient to safeguard this information and treat it as confidential.",
    "contradiction_score": 0.0020557809621095657,
    "kept": false,
    "reason": "low_contradiction"
  }
]